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improves patient QoL, incurs lower health-related costs, and offers a better economic 
utilization of health care resources relative to placebo.
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OBJECTIVES: Thalidomide (Thalidomide Pharmion® brand drug) combined with 
melphalan (M) and prednisone (P; MPT) increases progression-free survival (PFS) and 
overall survival (OS) compared to MP. We estimated life-time health and cost conse-
quences of MPT versus MP in Welsh patients with untreated multiple myeloma. 
METHODS: A Markov model with 4 health states: PFS with adverse event, PFS 
without adverse event, progressed, and dead. Transition probabilities and discontinu-
ation were derived from a clinical trial. Within the trial, subjects remained on treat-
ment for up to 12 6-week cycles or until progression or treatment-limiting toxicity. 
Treatment duration and average dose were modelled to match the trial. Thrombo-     
prophylaxis with MPT was included. Utilities associated with adverse events and          
disease states were obtained from the literature. Disease-management costs reﬂect 
clinical practice in Wales. Costs and outcomes were discounted at 3.5% per annum. 
RESULTS: The model estimated 25 months PFS with MPT versus 12 months with 
MP, with OS of 4.03 for MPT versus 2.88 years with MP; a gain of 0.9 (3.22 vs. 
2.32) QALYs. MPT’s higher lifetime costs (£16,937 vs. £1,524), lead to an ICER of 
£17,002 per QALY gained and £13,346 per life-year gained. Probabilistic sensitivity 
analyses showed that the results remained consistent through changes in model param-
eters as 95% of model replications produced costs between 12,750 and 26,500 per 
QALY gained. CONCLUSIONS: Replacing MP with MPT is a cost-effective strategy, 
which can deliver substantial improvements in PFS and OS in a life-limiting orphan 
disease in Wales.
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OBJECTIVES: The REDUCE trial examined whether chemoprevention with a 5-alpha 
reductase inhibitor, dutasteride, reduced the rate of prostate cancer (PCa) detection 
on biopsy. We examine the cost-effectiveness of using dutasteride compared with usual 
care in preventing PCa in men at increased risk as seen in REDUCE. METHODS: A 
Markov model was developed to compare the costs and outcomes of chemoprevention 
with dutasteride 0.5 mg/day or usual care in men 50–75 years, with serum prostate-
speciﬁc antigen (PSA) of 2.5–10 ng/mL (60 years) or 3.0–10 ng/mL ( 60 years), 
and a single negative, prostate biopsy in prior 6 months. The model simulated the 
REDUCE cohort of men annually through different health states (e.g. healthy male, 
PCa, BPH, PCa recurrence) over ten years. Risk of PCa for usual care and dutasteride 
patients was obtained from REDUCE, where dutasteride showed a reduced risk of 
23% and no signiﬁcant increase in high grade tumors. Additional beneﬁts in terms of 
reduction in benign prostate hyperplasia (BPH) progression (e.g. surgeries, acute 
urinary retention) were considered. Impact of adverse events (e.g., incontinence, erec-
tile dysfunction, ejaculatory dysfunction) were considered. Costs and utilities were 
obtained from the published literature. RESULTS: Dutasteride patients experienced 
fewer PCa’s (334 vs. 410 per 1000 patients) and increased costs ($17,237 vs. $13,800) 
compared with usual care patients. Although life years were not signiﬁcantly impacted, 
dutasteride patients incurred an increase in quality-adjusted life years (QALYs) of 
0.15. Chemoprevention with dutasteride was found to be cost-effective with an incre-
mental cost per QALY of $22,562. Results were robust to changes in parameters. 
CONCLUSIONS: Despite increased costs, due to taking a daily drug for prevention, 
the use of dutasteride is cost-effective in men at increased risk for PCa. Use of dutas-
teride for PCa prevention in the appropriate population could reduce the cost associ-
ated with the treatment of PCa and prevent reductions in quality of life associated 
with PCa treatment.
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OBJECTIVES: New therapies have recently been introduced for the treatment of 
mRCC. The objective of this analysis was to evaluate the cost-effectiveness of two 
such treatments, temisirolimus (TEM) and sunitinib (SUN) for the management of 
poor prognosis mRCC patients in Portugal. METHODS: A Markov model simulating 
disease progression in poor prognosis mRCC was developed to estimate cost-utility 
of TEM vs. SUN over 3-year time horizon. Patients in the model move through pro-
gression free survival (PFS), disease progression, or death. Transitions between health 
states were estimated from Weibull curves ﬁtted to overall survival (OS) and PFS of 
interferon (INF), the common comparator in TEM and SUN trials. Hazard ratios of 
treatment effect of TEM and SUN to INF were then applied. PFS and OS were based 
on poor prognosis patient population for TEM and SUN. On-treatment utility esti-
mates were based on EQ5D data. Local costs of drug, administration and medical 
follow-up were used. Analyses were run considering the uncertainty around PFS and 
OS measures using model generated 95% CI. Probabilistic sensitivity analysis was 
conducted to evaluate impact of assumptions on input parameters. RESULTS: The 
mean estimated total cost and QALYs for TEM was a18,757 (range a11,646 to 
a31,141) and 0.584 yrs. (range 0.388 yrs. to 0.794 yrs.). While for SUN the mean 
estimated total cost and QALYs was a14,323 (range a4,958 to a38,875) and 0.381 yrs. 
(range 0.125 yrs. to 0.831 yrs.). The mean incremental cost per QALY for TEM vs 
SUN was a21,783. Within the ranges of uncertainty, 20% of the time TEM could 
dominate SUN and 76% of the time TEM was more costly and more effective. CON-
CLUSIONS: TEM is projected to be cost effective compared to SUN in management 
of poor prognosis mRCC patients.
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OBJECTIVES: ZOL is efﬁcacious vs. PBO in reducing the risk of skeletal-related 
events (SREs) in lung cancer (LC) patients with bone metastases. Limited information 
exists on its economic impact. This study assessed the cost-effectiveness of ZOL in the 
LC setting in France (FR), Germany (DE), UK (UK), Portugal (PT), and the Nether-
lands (NL). METHODS: Comparisons of direct costs and quality-adjusted life years 
(QALY) between patients on ZOL vs. PBO were assessed using a literature-based 
model. Clinical information on survival, SRE incidence and infusions administered 
were obtained from a randomised clinical trial in LC patients, comparing 4 mg ZOL 
(every 3 weeks for 21 months) to PBO. Drug acquisition and administration costs 
were obtained from publicly available sources. SRE costs were obtained from Diag-
nosis-Related Group (DRG) tariffs and published information in FR, UK, and DE and 
from retrospective medical record reviews in NL and PT. RESULTS: The expected 
average survival for patients on ZOL and placebo was the same (8.5 months [median 
 5.89 months]). Per-patient (pp) SRE occurrence was projected to be higher and 
QALYs lower in PBO group (SREs  2.07; QALYs  0.292) vs. ZOL-treated patients 
(SREs  1.32; QALYs  0.352). ZOL drug-related costs ranged from a1510 in DE 
and a1484 per patient (pp) in UK. The use of ZOL was associated with a reduction 
in SRE costs ranging from a1.15 pp in FR to a1942 pp in NL. Overall, ZOL saved 
a319 pp in NL, followed by a291 in DE, a216 in UK, a67 in PT, and a2 in FR. In 
sensitivity analysis the cost per QALY gained remained under a50,000 in a wide range 
of scenarios. CONCLUSIONS: ZOL leads to fewer SREs and better estimated quality 
of life. This multinational evaluation reports ZOL to be a highly cost-effective treat-
ment relative to PBO for LC patients with bone metastases.
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OBJECTIVES: To develop a cost-effectiveness evaluation of the use of 
capecitabinedocetaxel vs gemcitabinedocetaxel in patients with recurrent breast 
cancer who previously failed to anthracycline chemotherapy and/or with metastatic 
disease. METHODS: A Markov model was built in order to show the clinic course 
of a cohort of patients with recurrent breast cancer who previously failed to anthra-
cycline chemotherapy and/or with metastatic disease in order to set a quantitative 
comparison between the costs associated in the schemes at the institutional Mexican 
context. The model includes three health states (no progression, progression and 
death), within a 12 months horizon. The outcomes obtained as effectiveness measure 
is Progression-Free Survival (PFS); in order to deﬁne resources and procedures to set 
costs a literature search for economic evaluation and different disease management 
alternatives was done; the costs used to run the model included diagnosis, treatment, 
following and medical support. The threshold to deﬁne a therapy as cost-effective was 
ﬁxed at US$25,020.00 (least than three times Mexican GDP per capita) following the 
recommendations of WHO’s Commission on Macroeconomics and Health. RESULTS: 
The total management cost at 12 moths with capecitabinadocetaxel is US$23,117.90 
vs US$23,978.12 for gemcitabinadocetaxel. The Cost-effectiveness plane indicates 
capecitabinadocetaxel is a cost-effective therapy; with a probability of 0.50 of being 
cost saving and 0.80 to be cost-efective is at a US$25,020.00 threshold. CONCLU-
SIONS: Results show that capecitabinedocetaxel is a cost effective therapy when 
comparing with gemcitabinedocetaxel therapy in ﬁrst line therapy for patients with 
breast cancer who previously failed to anthracycline chemotherapy and/or with meta-
static disease.
